据一财,先声药业对阿尔茨海默病药物的研发已经停止。2021年6月,先声药业与Vivoryon达成超5亿美元的合作,获得相关药物在大中华区开发和商业化权益,并于2022年在国内获批临床试验。不过,先声药业研发阿尔茨海默病药物的总体投入金额尚不确定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.